ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company focusing on rationally designed immunotherapeutics against cancer and persistent viral infections, today announced that its fully-owned subsidiary ISA Therapeutics B.V. has closed an R&D agreement with Japan-based Shin Nippon Biomedical Laboratories, Ltd. (SNBL) to explore a novel nasal delivery for ISA’s cervical cancer immunotherapeutic.
ISA Pharmaceuticals announces start of first Phase I/II clinical trial of its SLP®-AMPLIVANT® conjugatesPublished : Thursday, February 26, 2015
ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company focusing on rationally designed immunotherapeutics against cancer and persistent viral infections, has announced the start of an investigator-initiated Phase I/II clinical trial of a novel immunotherapeutic based on ISA Pharmaceuticals´ platform technology. The trial will be conducted by the Department of Clinical Oncology at Leiden University Medical Center in The Netherlands. The study will investigate the biological activity and safety of the compound in head and neck cancer patients who tested positive for human papilloma virus type 16 (HPV16). HPV infections, in particular HPV16, are one of the major causes of this type of cancer.
Lugus is the name of the new breeding ground for prospective entrepreneurs in the University of Leiden. In the former Chambre of Commerce site next to the Leiden train station a group of proactive students are working on their startups. In that former Chambre of Commerce building where once plenty of new companies were legally established, entrepreneurship is now flourishing once more.
Galapagos NV, a clinical stage biotechnology company focused on developing novel mode of action medicines, announced that the last patient in the DARWIN 1 trial with filgotinib has completed the 12 week visit. This last patient's 12 week visit triggers the clinical research organization's process of final 12 week data collection from all 599 patients enrolled in the trial, to be followed by database lock and analysis. As this process takes approximately 7 to 8 weeks, Galapagos expects to announce topline results by mid-April 2015.
On the 6th of February 120 students celebrated their graduation of the ‘Leren over Leven’ program in Leiden Bio Science Park. The oncology team of Janssen Biologics introduced an educational high school outreach program for high school students 4 years ago. The goal of this program is to give high school students more insight in the field of oncology (both pharmaceutical and healthcare) and is a connection between the world of school and the world of work.
> Read more in Dutch
The pharmaceutical research community meets on 10 March 2015 for the first Leiden Pharma Science Symposium of 2015. This tri-yearly event has been created to stimulate collaboration and exchange about research ideas within the Leiden Bio
Science Park. It is organized by Prof. Henk-Jan Guchelaar, LUMC, Prof. Adam Cohen and Dr Robert Rissmann, CHDR, Prof. Piet Hein van der Graaf, LACDR, and Dr Saco de Visser, LBSP.
All researchers are welcome!
Therefore, all Technolab Friends and school in and around Leiden can sign up for a free workshop!
We were presented with the great opportunity to link with entrepreneur, MIT guest lecturer and business ambassador Jos Scheffelaar! Jos makes himself available to share insights into the Boston high-tech cluster with us, to answer questions about how to best do business there and to simply link up with him and his network. He will host an info&network session next Monday, Feb 23rd, as of 16.00 in the auditorium of BioPartner1 (J.H. Oortweg 19 Leiden).
NIZO food research and BaseClear, the genomics solution provider, have joined forces to offer a complete solution package for microbial genomics research. The combination of BaseClear’s state of the art genomic facilities and expertise, and NIZO’s expert knowledge of bacterial genetics and extended bioinformatics analysis will help customers to improve the selection of micro-organisms for industrial applications and perform more cost-effective projects. This will enable industry and academia to obtain faster and more accurate data, with integrated statistics and visualisation, which will speed up research and development of e.g. health mediating products or industrial microbes.
'' Thanks to the heartwarming support of the ‘BankGiro Lottery’ the Netherlands will soon stand face to face with the queen of the dinosaurs, "said Edwin van Huis, director of Naturalis. "We are delighted that we now have the amount to present the most extraordinary fossil ever in the Netherlands." During the ‘Goed Geld Gala' Naturalis received a cheque of 1.2 million euros.
> Read more in Dutch
Prosensa Holding N.V. ("Prosensa" or the "Company"), the biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, announced that, on February 11, 2015, it will file a Form 25, Notification of Removal from Listing and/or Registration under Section 12(b) of the Securities Exchange Act of 1934 (the "Exchange Act") (the "Form 25"), with the Securities Exchange Commission ("SEC") in order to voluntarily delist the registered shares of the Company, nominal value €0.01 per share (the "Shares") from the NASDAQ Global Select Market ("NASDAQ"), which will become effective 10 days after filing. NASDAQ has advised the Company that it will suspend trading of the Shares after the market closes on February 11, 2015. As such, shareholders of the Company will not be able to trade their shares on NASDAQ thereafter
Galapagos NV announced that the Flemish Agency for Innovation through Science and Technology (IWT) has awarded a €1.6 million grant to support the development of new antiviral therapies against hepatitis B, in a collaboration project with Prof. Johan Neyts of the Rega Institute of the University of Leuven and Prof. Stephan Urban of the University Hospital in Heidelberg.
Prosensa Holding N.V., the biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, announced that it intends to voluntarily delist the registered shares of the Company, nominal value €0.01 per share (the "Shares"), from the NASDAQ Global Select Market ("NASDAQ"). Upon satisfaction of the applicable requirements for deregistration, Prosensa also intends to deregister the Shares under the Securities Exchange Act of 1934, as amended (the "Exchange Act") and to suspend its reporting obligations under the Exchange Act once it is eligible to do so.
Friday Januay 23rd, policy makers of MPs in the VWS committee at the Dutch Parliament visited several companies at Leiden Bio Science Park. They were invited by the science park foundation and industry organizations Nefarma and HollandBIO. The purpose of the meeting was to portray the biopharmaceutical sector and its issues. The MP staff members were interested in the companies views on The Hague VWS policies. Companies presented their companies and voiced their concerns.
The first Life Sciences Café of this year and the Leiden Bio Science Park New Year’s reception that followed afterwards were very crowded and held in a very vibrant and good atmosphere. Over 130 people joined and enjoyed the speeches of the new directors of Leiden Bio Science Park foundation, BioPartner Center Leiden and LURIS and the new chairman of the Entrepreneurial Association OV BSP.
The Leiden Bio Science Park newsletter is a free bimonthly email newsletter in English. The newsletter offers general life science news, news from the companies and institutions, a company profile, events and jobs.
click here to subscribe